Cunningham K A, Appel J B
J Pharmacol Exp Ther. 1986 May;237(2):369-77.
Male rats (N = 24) were trained to discriminate 1-(m-trifluoromethylphenyl)piperazine (TFMPP) (0.8 mg/kg) from saline in a two-lever, drug discrimination situation. 5-Hydroxytryptamine (5-HT) agonists such as fenfluramine (0.8-1.6 mg/kg), m-chlorophenylpiperazine (0.1-1.6 mg/kg) and RU 24969 (0.1-1.6 mg/kg) mimicked TFMPP; 8-hydroxy-2-(di-n-propylamino)tetralin (0.02-0.32 mg/kg) and quipazine (0.2-3.2 mg/kg) elicited saline lever responding; d-lysergic acid diethylamide (0.1-0.16 mg/kg) produced intermediate results. The 5-HT antagonists BC 105 (1.6-12.8 mg/kg), bromolysergic diethylamide (0.8-1.28 mg/kg), ketanserin (0.8-6.4 mg/kg), Ly 53857 (0.2-1.6 mg/kg) and pirenperone (0.08-0.64 mg/kg) failed to attenuate the TFMPP cue; metergoline (0.4-6.4 mg/kg) and spiperone (0.08-1.28 mg/kg) decreased drug lever responding by as much as 60%. These data suggest that 5-HT agonists are not identical and that drug discrimination procedures can differentiate among them. Given that there is strong evidence to support the existence of heterogeneous 5-HT receptors, the present results also suggest that TFMPP acts through mechanism(s) similar to those of the novel 5-HT1 agonists m-chlorophenylpiperazine and RU 24969; these actions can be differentiated from those underlying d-lysergic acid diethylamide, quipazine and 2,5-dimethoxy-4-methylamphetamine, which are attenuated by putative 5-HT2 antagonists. Thus, the authors propose a role for 5-HT1 receptors in mediating the stimulus effects of TFMPP, although further research is necessary to identify functional antagonists of such systems.
雄性大鼠(N = 24)在双杠杆药物辨别实验中接受训练,以区分1-(间三氟甲基苯基)哌嗪(TFMPP)(0.8毫克/千克)和生理盐水。5-羟色胺(5-HT)激动剂如芬氟拉明(0.8 - 1.6毫克/千克)、间氯苯哌嗪(0.1 - 1.6毫克/千克)和RU 24969(0.1 - 1.6毫克/千克)可模拟TFMPP的作用;8-羟基-2-(二正丙基氨基)四氢萘(0.02 - 0.32毫克/千克)和喹哌嗪(0.2 - 3.2毫克/千克)引发对生理盐水杠杆的反应;d-麦角酸二乙酰胺(0.1 - 0.16毫克/千克)产生中间结果。5-HT拮抗剂BC 105(1.6 - 12.8毫克/千克)、溴麦角酸二乙酰胺(0.8 - 1.28毫克/千克)、酮色林(0.8 - 6.4毫克/千克)、Ly 53857(0.2 - 1.6毫克/千克)和匹仑哌隆(0.08 - 0.64毫克/千克)未能减弱TFMPP的提示作用;美替拉酮(0.4 - 6.4毫克/千克)和螺哌隆(0.08 - 1.28毫克/千克)可使药物杠杆反应降低多达60%。这些数据表明5-HT激动剂并不相同,并且药物辨别程序可以区分它们。鉴于有强有力的证据支持存在异质性5-HT受体,目前的结果还表明TFMPP通过与新型5-HT1激动剂间氯苯哌嗪和RU 24969类似的机制起作用;这些作用可与d-麦角酸二乙酰胺、喹哌嗪和2,5-二甲氧基-4-甲基苯丙胺的作用相区分,后三者的作用可被假定的5-HT2拮抗剂减弱。因此,作者提出5-HT1受体在介导TFMPP的刺激作用中起作用,尽管需要进一步研究来确定此类系统的功能性拮抗剂。